6 Result(s)
within
Juthamas Sukbuntherng
-
Article
The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure
This drug-interaction study evaluated the effect of omeprazole, a proton-pump inhibitor, on ibrutinib’s pharmacokinetics (PK) in healthy participants.
-
Article
Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study
The author would like to correct the affiliations and conflict of interest in the publication of the original article. The corrected details are given below for your reading.
-
Article
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study
Ibrutinib is an orally administered, irreversible Bruton’s tyrosine kinase inhibitor for treatment of B-cell malignancy. This study evaluated the effects of single-dose ibrutinib at therapeutic and supratherap...
-
Article
Open AccessThe effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
To assess ibrutinib pharmacokinetics under fasted and fed conditions, impact of food-intake timing, and the safety and tolerability.
-
Article
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
Ibrutinib is an oral Bruton’s tyrosine kinase inhibitor, recently approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) patients with at least one prior therapy. We d...
-
Article
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
The purpose of these extensive non-clinical studies was to assess pharmacokinetics and dispositional properties of sunitinib and its primary active metabolite (SU12662).
